Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

CRB-601

Other · developed by Corbus Pharmaceuticals

Phase 1/2 Most advanced trial
CRBP Developer
1 Registered trials

What is CRB-601?

CRB-601 is an investigational drug studied in Solid Tumor.

At a glance

Drug type
Other
Therapy area
Oncology
Developer
Corbus Pharmaceuticals Inc. (CRBP)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06603844 Phase 1/2 Solid Tumor Recruiting CRBP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Solid Tumor

More from Corbus Pharmaceuticals

CRB-913 Phase 1 Extension Phase 2 JBT-101 Phase 3 Sutantatug Envedotin Phase 3

Follow CRBP, the company behind CRB-601

See CRBP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRBP catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.